Citations

Clear

3030 citation(s) found for "Susan, M".

Impact of Prolonged Seizures on Patients’ and Caregivers’ Quality of Life (P1-9.014)
Kaye, Danya, Manzo, Michelle, Wilkinson, Andrea , Laloyaux, Cédric, Burns, Rebecca, Piña-Garza, J. Eric , Sirven, Joseph, Bhatia, Tanya, Cunneen, Shalee, Meitzler, Shelly, Linn, Susan, Kaye, Danya, Manzo, Michelle, Wilkinson, Andrea, Burns, Rebecca

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210527 Get It

Late Adult Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Clinical Characterization and Predictors of Outcome (P7-8.005)
Redenbaugh, Vyanka , Lopez, Alfonso, Valencia, Cristina Gutiérrez , Guo, Kai , Horsman, Susan, Tajfirouz, Deena , Eggenberger, Eric , Chodnicki, Kevin D. , Tillema, Jan‐Mendelt , Chen, John , Dinoto, Alessandro , Cacciaguerra, Laura , Vorasoot, Nisa , Valencia, Cristina, Thakolwiboon, Smathorn , Syc‐Mazurek, Stephanie B. , Tisavipat, Nanthaya , Pless, Misha L , Pittock, Sean J. , Flanagan, Eoin P.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211822 Get It

Elevated Risk of Multiple Sclerosis and Related Outcomes in Epstein-Barr Virus-Positive Infectious Mononucleosis: A Population-Based Cohort Study (P12-10.001)
Diaz‐Decaro, John , Sauver, Jennifer St., Fan, Chun , Hall, Susan A. , Senko, Enejda, Garcia, Ali A. Duarte, Crowson, Cynthia S. , Yang, Jeffrey X. , Keegan, Mark T. , DaVeiga, Sigrid Payne, Buck, Philip O. , St Sauver, Jennifer L , Jacobson, Robert M.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000212313 Get It

The Urgent Need for Evidence Over Anecdote: Equipoise in the ExTINGUISH Clinical Trial in Anti-NMDAR Encephalitis (P7-8.016)
Smith, Tammy, Peterson, Lisa K. , Ζεκερίδου, Αναστασία , Coffey, Christopher S. , Banwell, Brenda, Dialino-Felix, Annalisa, Flavin, Susan , Dill, L.V., Cho, Hyun , Day, Gregory S. , Clardy, Stacey , Clardy, Stacey L , Day, Gregory S , Hoshina, Yoji , Smith, Tammy, Wong, Ka-Ho , Aboseif, Albert , Wright, Melissa A. , Dill, Lisa, Dalmau, Josep , Titulaer, Maarten J

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211728 Get It

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia
Rankin, Alexander W. , Hoang, Chloe, Semchenkova, Alexandra , Myers, Regina M. , Wang, Hao‐Wei , Kovach, Alexandra E. , Yuan, Constance M. , Colon, Dana Delgado, Vasseur, Loïc , John, Samuel , Lyons, Kaylyn Utley , Friedes, Barbara D., Alonso‐Saladrigues, Anna , Abdel‐Azim, Hisham , Balducci, Estelle , Aljudi, Ahmed Assim , Balsat, Marie , Biery, D. N. , Chamdin, Aghiad, Cuevo, Raymund S., Dickens, David S. , Duffner, Ulrich, Elliott, Michelle A. , Escherich, Gabriele , Fernandes, Sneha, Fitzjohn, Mandi R., Gahvari, Zhubin, He, Rui , Harrison, Cynthia , Hergott, Christopher A. , Hsieh, Emily M. , Larson, Daniel P. , Lee, Benjamin J. , Leguay, Thibaut , Mangaonkar, Abhishek A. , Mezger, Kerstin, Pacenta, Holly , Provost, Marlie R. M., Puri, Latika, Raikar, Sunil S. , Martinez, Armando, Bristol, Isabella Quijada, Murphy, Kyle, Reiman, Lauren T. , Redell, Michele S. , Reed, Kelly, Guépin, Gabrielle Roth, Savaşan, Süreyya , Schafernak, Kristian T. , Stevens, Alexandra M. , Talleur, Aimee C. , Carapia, Naomi Torres, Vargaftig, Jacques , Vatsayan, Anant , Wölfl, Matthias , Rives, Susana , Sasaki, Koji , Davis, Kara L. , Ghorashian, Sara , Jacoby, Elad , Попов, А. М. , Lamble, Adam J. , Rankin, Alexander W , Semchenkova, Alexandra , Myers, Regina M , Zerkalenkova, Elena , Wang, Hao-Wei , Kovach, Alexandra E , Yuan, Constance M , Vasseur, Loïc , Alonso-Saladrigues, Anna , Balducci, Estelle , Aljudi, Ahmed Assim , Chang, Bill H , Cuevo, Raymund S , De Moerloose, Barbara , Dickens, David S , Duployez, Nicolas , Elliott, Michelle Ann, Harrison, Cynthia , Kim, Annette S , Kuo, Dennis J , Larson, Daniel P , Lee, Benjamin J , Leguay, Thibaut , Lindsley, R Coleman , Puri, Latika , Raikar, Sunil S , Rubinstein, Jeremy , Schafernak, Kristian , Talleur, Aimee , Vatsayan, Anant , Wölfl, Matthias , Rives, Susana , Fabrizio, Vanessa A , Sasaki, Koji , Boissel, Nicolas , Rheingold, Susan R , Davis, Kara L , Ghorashian, Sara , Popov, Alexander , Shah, Nirali N , Silbert, Sara K. , Zerkalenkova, Elena , Colon, Dana Delgado, Bataller, Alex , Biery, D. Nathan, Chaer, Firas El , Grupp, Stephan A. , Pan, Jing , Martinez, Armando, Murphy, Kyle, Zhao, Liping, Aldoss, Ibrahim

Mayo Clinic

Blood | April 7, 2025 | Volume: 146 | Issue: 4 | Pages: 437-455

10.1182/blood.2024026655 | PMID 40193715 Get It

Abstract Lineage switch (LS), defined as the immunophenotypic transformation of acute leukemia, has emerged as a mechanism of relapse after antigen-targeted immunotherapy, which is associated with dismal outcomes. Through an international collaborative effort, we identified cases of LS after a host of antigen-targeted therapies (eg, CD19, CD22, CD38, and CD7), described how LS was diagnosed, reviewed treatment approaches, and analyzed overall outcomes for this form of postimmunotherapy relapse. Collectively, 75 cases of LS were evaluated, including 53 (70.7%) cases of B-cell acute lymphoblastic leukemia (B-ALL) transforming to acute myeloid leukemia (AML), 17 (22.7%) cases of B-ALL transforming to mixed phenotypic acute leukemia (MPAL)/acute leukemias of ambiguous lineage (ALAL), and 5 (6.7%) cases of rare LS presentation (ie, T-cell ALL to AML). An additional 10 cases with incomplete changes in immunophenotype, referred to as “lineage drift” were also described. With a primary focus on the 70 cases of LS from B-ALL to AML or MPAL/ALAL, LS emerged at a median of 1.5 months (range, 0-36.5) after immunotherapy, with 81.4% presenting with LS within the first 6 months from the most proximal immunotherapy. Although most involved KMT2A rearrangements (n = 45, 64.3%), other rare cytogenetic and/or molecular alterations were uniquely observed. Treatment outcomes were generally poor, with remission rates of <40%. The median overall survival after LS diagnosis was 4.8 months. Outcomes were similarly poor for those with rare immunophenotypes of LS or lineage drift. This global initiative robustly categorizes lineage changes after immunotherapy and, through enhanced understanding, establishes a foundation for improving outcomes of LS.
Spatial synaptic connectivity underlies oligodendroglioma evolution and recurrence
Raleigh, David R. , Mirchia, Kanish , Oten, Sena, Ambati, Vardhaan , Vasudevan, Harish N. , Young, Jacob, Taylor, Jennie , Krishna, Saritha, Brang, David , Phillips, Joanna J. , Chang, Susan M. , Hervey‐Jumper, Shawn L. , Raleigh, David , Ambati, Vardhaan , Vasudevan, Harish , Taylor, Jennie W , Phillips, Joanna , Perry, Arie , de Groot, John , Hervey-Jumper, Shawn L , Picart, Thiébaud , Nguyen, Minh, Perry, Arie , Berger, Mitchel S. , Groot, John de

Mayo Clinic

No container title available | April 4, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6299872/v1 | PMID 40235496 Get It

Abstract Oligodendrogliomas are initially slow-growing brain tumors that are prone to malignant transformation despite surgery and cytotoxic therapy. Understanding of oligodendroglioma evolution and new treatments for patients have been encumbered by a paucity of patient-matched newly diagnosed and recurrent tumor samples for multiplatform analyses, and by a lack of preclinical models for interrogation of therapeutic vulnerabilities that drive oligodendroglioma growth. Here we integrate spatial and functional analyses of tumor samples and patient-derived organoid co-cultures to show that synaptic connectivity is a hallmark of oligodendroglioma evolution and recurrence. We find that patient-matched recurrent oligodendrogliomas are enriched in synaptic gene expression programs irrespective of previous therapy or histologic grade. Analyses of spatial, single-cell, and clinical data reveal epigenetic misactivation of synaptic genes that are concentrated in regions of cortical infiltration and can be used to predict eventual oligodendroglioma recurrence. To translate these findings to patients, we show that local field potentials from tumor-infiltrated cortex at the time of resection and neuronal hyperexcitability and synchrony in patient-derived organoid co-cultures are associated with oligodendroglioma proliferation and recurrence. In preclinical models, we find that neurophysiologic drugs block oligodendroglioma growth and pathologic electrophysiology. These results elucidate mechanisms underlying oligodendroglioma evolution from an indolent tumor to a fatal disease and shed light on new biomarkers and new treatments for patients.
Approaches to Timescale Choice in Cognitive Aging Research and Potential Implications for Estimated Exposure Effects: Coordinated Analyses in 10 Cohorts of Older Adults
Hayes‐Larson, Eleanor , Andrews, Ryan M. , Kezios, Katrina , Bercu, Ariane, Rouanet, Anaïs , Helmer, Catherine , Crane, Paul K. , Klinedinst, Brandon S. , McEvoy, Linda K. , Weuve, Jennifer , Rajan, Kumar B. , Shaw, Crystal , Sims, Kendra D. , Therneau, Terry M. , Petersen, Ronald C., Bouteloup, Vincent , Gross, Alden L. , Albert, Marilyn, Morris, John C., Resnick, Susan M. , Turney, Indira C. , Vonk, Jet M. J. , Avila‐Rieger, Justina , Weigand, Alexandra J. , Chen, Ruijia , Wang, Jingxuan , Mayeda, Elizabeth Rose , Klinedinst, Brandon S , McEvoy, Linda K , Weuve, Jennifer , Mez, Jesse , Sims, Kendra D , Therneau, Terry , Albert, Marilyn S. , Masters, Colin L , Resnick, Susan M , Maruff, Paul , Manly, Jennifer J , Turney, Indira C , Vonk, Jet M J , Avila-Rieger, Justina , Weigand, Alexandra , Mayeda, Elizabeth Rose , Gibbons, Laura E. , Nichols, Emma , Rajan, Kumar Bharat , Hwang, Phillip H , Mez, Jesse , Farina, Mateo P. , Morris, John C. , Masters, Colin L. , Maruff, Paul , Manly, Jennifer J. , Proust‐Lima, Cécile

Mayo Clinic

Epidemiology | March 31, 2025 | Volume: 36 | Issue: 4 | Pages: 560-571

10.1097/ede.0000000000001859 | PMID 40164562 Get It

Background: Cognitive change is an important factor in understanding dementia. Estimating effects of exposures on cognitive change requires choosing an analytical timescale, typically time on study or current age. There is limited consensus regarding timescale choice in epidemiologic cognitive aging research. Methods: Using a coordinated analytic approach in 10 cohorts of older adults, we evaluated whether estimated effects of two exposures on memory change differed depending on timescale (time on study or current age). We modeled effects of apolipoprotein-E (APOE) ε4 genotype (a time-invariant exposure) and diabetes (a potentially time-varying/acquired exposure evaluated at baseline) using mixed-effects models with linear and nonlinear time specifications for both timescales. Results: Among APOE ε4 carriers, model-estimated memory scores at baseline (time on study timescale) or at each cohort’s median baseline age (current age timescale) were lower, and the average rate of decline was faster than among APOE ε4 noncarriers. Model-estimated memory scores at baseline or at median baseline age were generally similar across baseline diabetes status, with variability across cohorts in the diabetes-memory change association. In some cohorts, trends in diabetes-memory change associations differed in direction across timescales. Conclusions: Timescale was largely inconsequential for estimated effects of APOE genotype, but yielded differences in estimated diabetes effects, raising questions about the appropriate scale. The current age scale may be problematic because diabetes was measured heterogeneously in age across individuals, a common issue in aging cohorts. Our work demonstrates approaches to evaluate alternative timescales, including in multicohort analyses, and highlights potential implications for estimated exposure effects on cognitive change.
FP5.4 Labral re-fixation versus debridement for symptomatic femoroacetabular impingement (FAI): A Matched Analysis at Mean 10-year outcomes in a Prospective, Multi-Center Cohort
Bedi, Asheesh , Nepple, Jeffrey J. , Thapa, Susan , Millis, Michael B. , Kim, Young‐Jo , Group, ANCHOR Study, Clohisy, John C., Beaulé, Paul E. , Sierra, Rafael J. , Group, ANCHOR Study, Clohisy, John C.

Mayo Clinic

Journal of Hip Preservation Surgery | March 31, 2025 | Volume: 12 | Issue: Supplement_1 | Pages: i14-i14

10.1093/jhps/hnaf011.042 Get It

Abstract Introduction: Labral injury at the time of open and arthroscopic hip preservation surgery for symptomatic femoroacetabular impingement (FAI) is managed with debridement versus refixation by the treating surgeon based on tear pattern, tissue quality, and hip morphology. While refixation has been favored based on mid-term outcomes in some series, differences in the long-term patient reported outcomes (PROMS) have not been defined in well-designed and matched prospective series. Methods: This study consisted of a prospective, multi-center cohort that underwent primary surgical treatment for symptomatic FAI. Patients were included if they underwent corrective osteoplasty and a labral refixation or a labral debridement procedure. Using a ratio of 1:1, hips with labral refixation and labral debridement were matched by age, sex, and surgical approach. Postoperative assessments were conducted at a minimum 8 years after surgery using PROMS and assessment of reoperations. Results: A total of 237 hips (n=188 labral refixation, n=49 labral debridement) met the inclusion criteria for the current study. 48 hips from the labral refixation and 48 hips from debridement groups with mean follow-up of 10.3±1.7 years and 10.6±2.1 years respectively were included. No significant differences were observed in the femoral head, acetabular cartilage grade, or labral grade between the groups. The mHHS improved 19.8±19.6 and 23.4±16.8 from baseline to the final follow-up in the labral refixation and debridement groups, respectively (p=0.43). There were no significant differences in PROMS between the labral refixation and debridement groups. Overall, 66% and 76% of the labral refixation and debridement groups achieved the MCID for the mHHS respectively (p=0.30). There were more revision surgeries with labral refixation than with debridement (10.4% vs. 2.1%, p=0.09), but more conversions to total hip replacement in the labral debridement group (8.3% vs. 4.2%, p=0.38), but neither of these differences were statistically significant. Discussion: Both labral refixation and debridement are effective with durable improvement in PROMS at a mean of 10 years in a prospective cohort of patients treated surgically for symptomatic FAI. No significant differences in baseline or final PROMS were observed, and similar rates of revision and conversion to hip replacement were observed in the debridement and refixation groups.
EP6.75 Survivorship of first-generation FAI surgery at an average 10 year follow-up: A prospective, multicenter cohort study
Hood, Hunter, Nepple, Jeffrey J. , Thapa, Susan , Kim, Young-Jo, Sink, Ernest L. , Group, ANCHOR Study, Clohisy, John C, Sierra, Rafael J. , Beaulé, Paul E. , Group, ANCHOR Study, Clohisy, John C

Mayo Clinic

Journal of Hip Preservation Surgery | March 30, 2025 | Volume: 12 | Issue: Supplement_1 | Pages: i113-i113

10.1093/jhps/hnaf011.364 Get It

Abstract Background: Long-term outcomes of FAI surgery are critical to understand it’s hip preserving ability, yet few studies have reported mid to long-term survivorship following FAI surgery. The purpose of this study was to report rates of treatment failure after first-generation FAI surgery at an average 10- year follow-up. Methods: A prospective, multicenter cohort study assessed patients treated for FAI with hip arthroscopy or surgical dislocation by seven surgeons at four institutions from 2008 to 2012. Inclusion criteria included primary surgery and diagnosis of isolated cam or combined cam/pincer type FAI. At an average 10-year follow-up, 362/452 eligible hips (80.1%) achieved follow-up. Cox proportional hazards model was used to identify predictors of conversion to total hip arthroplasty (THA). Results: Three hundred and sixty two hips were evaluated at a mean of 10.0 ± 2.3 years follow-up. At time of final follow-up, 34 hips (9.2%) had undergone conversion to THA at a mean of 5.2 ± 3.1 years post-operatively. An additional 18 patients (4.9%) underwent non-arthroplasty revision preservation surgery at a mean of 2.0 ± 1.5 years post-operatively. The Kaplan Meier survivorship rates after 5 and 10 years of surgery were 94.9% and 95.2% for conversion to THA and 91 % and 95.2% for revision hip preservation. Older age (HR:1.06, CI: 1.01-1.10; p=0.009), BMI≥30 (HR:4.14, CI:1.52-11.24, p=0.005), male sex (HR:3.23, CI: 1.18-9.09, p=0.02), and lower baseline mHHS (HR:1.03, CI: 1.01-1.04, p=0.01) were significant predictors of conversion to THA. Conclusion: This study demonstrates that FAI surgery yields durable outcomes with the majority of patients (85.9%) not requiring revision surgery or conversion to total hip arthroplasty at an average 10 years. Age 30 years, male sex, and obesity were significantly associated with the risk of THA conversion.
Interactions between genetic and epidemiological factors influencing mammographic density
Suger, Austin Hammermeister , Chen, Hongjie , Fan, Shaoqi , Bolla, Manjeet K. , Michailidou, Kyriaki , Wang, Qin , Fasching, Peter A. , Haeberle, Lothar, Aronson, Kristan J. , Eccles, Diana M, Evans, D. Gareth , Astley, Susan , Hall, Per, Pharoah, Paul D P, Antoniou, Antonis C, García‐Closas, Montserrat , González, Amy Berrington de , Easton, Douglas F. , Vachon, Celine M. , Lindström, Sara, Eccles, Diana , Fan, Shaoqi , Bolla, Manjeet K , Dennis, Joe , Michailidou, Kyriaki , Wang, Qin , Stone, Jennifer , Yadav, Siddhartha , Milne, Roger L , Norman, Aaron, Hall, Per N , Czene, Kamila , Pharoah, Paul D P , García-Closas, Montserrat , Easton, Doug , Eccles, Diana , Evans, D Gareth , Berrington de Gonzalez, Amy , Haas, Cameron B. , Scott, Christopher G. , Dunning, Alison M. , Stone, Jennifer , Gago-Domínguez, Manuela , Castelao, Jose E. , Murphy, Rachel A. , Couch, Fergus J. , Yadav, Siddhartha , Milne, Roger L. , Hopper, John L. , Norman, Aaron D. , Eliassen, A. Heather , Tapper, William , Czene, Kamila , Antoniou, Antonis C. , Gierach, Gretchen L. , Tamimi, Rulla M. , Vachon, Celine M. , Harrison, Tabitha A.

Mayo Clinic

American Journal of Epidemiology | March 30, 2025 | Volume: 195 | Issue: 5 | Pages: 1231-1241

10.1093/aje/kwaf067 | PMID 40153356 Get It

Abstract Studies have identified genetic and epidemiologic factors associated with mammographic density (MD) phenotypes. However, MD-associated genetic variants only account for a small proportion of the total estimated heritability. Interrogating interactions between genetic and epidemiologic factors could potentially identify additional MD-associated loci, expand our understanding of the genetic basis of MD phenotypes, and clarify how epidemiologic factors modulate relationships between genetic variants and MD. We conducted six separate genome-wide, gene–environment (GxE) interaction analyses, applying 2 degrees of freedom (df) and 1df interaction tests, for each of three MD phenotypes (percent density, dense area (DA), and nondense area (NDA)). The six epidemiologic factors considered were height, ever parous, parity, ever menopausal hormone therapy, ever breastfeeding, and months of breastfeeding. We included European ancestry participants from multiple studies within the Markers of Density consortium and the Breast Cancer Association Consortium (n = 4895-16 218 depending on specific analyses). We identified 11 loci with genome-wide significant (P < 5 × 10−8) interaction tests including two novel common genetic signals interacting with parity (8p21.2) and ever breastfeeding (19p13.2) for NDA. Our results suggest that epidemiologic risk factors might influence relationships between common genetic variants and MD phenotypes at particular genomic loci.